OPEN END TURBO OPTIONSSCHEIN SHORT - NOVO-NORDISK B | Market Closed - BOERSE MUENCHEN 11:56:43 31/05/2024 pm IST | ||
| 4.76 EUR | -2.46% |
|
| 1 month | -6.30% | ||
| 3 months | -24.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 4.76 | -2.46% |
| 30/24/30 | 4.88 | -1.71% |
| 29/24/29 | 4.965 | +0.57% |
| 28/24/28 | 4.937 | +1.98% |
| 27/24/27 | 4.841 | +1.96% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 11:56 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG05G6 |
| ISIN | DE000GG05G62 |
| Date issued | 23/11/2023 |
| Strike | 1,282 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.664 € |
|---|---|
| Lowest since issue | 4.597 € |
| Spread | 0.05 € |
| Spread % | 1.04% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
